Oura’s acquisition of health tech startup Counsel Health is raising conflict-of-interest concerns for Eli Lilly, as experts say GLP-1 drugmakers increasingly promote telehealth prescribers. Lilly has featured Counsel Health as a provider for patients seeking GLP-1 prescriptions through LillyDirect. Under the announced deal, Counsel clinicians would gain access to data gathered through Oura’s smart ring, which could affect diagnostic and treatment decisions. Lilly agreed to buy $50 million of Oura stock if certain conditions are met, though STAT reports those conditions have not yet been satisfied. The move spotlights how wearable-linked data channels and branded telehealth models can blur incentives when drug manufacturers benefit financially from the digital intermediaries they promote.